The Longevity Audit: What to Check Before You Optimize

Name: The Longevity Audit: What to Check Before You Optimize
Creator: Hillary Lin, MD
Published: 2026-06-07
Keywords: longevity audit, health audit checklist, preventive health checklist, healthspan checklist, biomarkers for longevity, what health screenings do I need, preventive medicine checklist, longevity checklist, blood pressure ranges, ApoB Lp(a), A1c ranges, cancer screening guide, healthspan guide, what labs to check for longevity, MCED tests, whole-body MRI screening, tobacco nicotine cessation, asymmetric health risks

A longevity audit is prevention triage: close symptoms and abnormal results first, then blood pressure, atherogenic lipids, metabolic risk, screening, sleep apnea when suspected, kidney/liver risk, and asymmetric safety loops—including tobacco/nicotine exposure—before advanced optimization.

Hillary Lin, MD·Reviewed June 7, 2026·12 min read

Order matters

Start with warning lights and fatal loops. Put tobacco/nicotine, alcohol, medication, vaccine, and safety issues in the asymmetric-risk review. Add advanced tests only when they change care.

Use ranges wisely

Some cutoffs diagnose disease; others are risk anchors. The useful question is what result changes the next decision.

Build reserve

After preventable risk is handled, fitness, strength, sleep, nutrition, sensory health, and social connection become the healthspan work.

Web-native Longevity Audit priority map showing triage, fatal loops, asymmetric risks, physiologic reserve, and experiments in descending priority order.

Short answer

A longevity audit is health spring cleaning with triage. It is not a scavenger hunt for the newest biomarker. It asks: what is the most preventable, measurable thing most likely to shorten my life or shrink my independence, and have I actually closed that loop?

The order matters. First, follow up symptoms and known abnormal results. Then close the fatal loops: blood pressure, atherogenic lipoproteins, metabolic risk, age- and risk-appropriate cancer screening, sleep apnea when suspected, and kidney/liver/vascular risk. Put tobacco and nicotine exposure in the asymmetric-risk review: the downside is huge, the first move is concrete, and it deserves more than a throwaway checkbox.

Advanced biomarkers, hormones, wearables, genetics, MCED blood tests, whole-body MRI, rapamycin debates, and n=1 experiments move up only when they would change a decision and the follow-up plan is real. Interesting is not the same as first.

Protocol

Longevity audit priority order

Priority tier

What belongs here

Why it comes first

Examples

Priority tier

1. Warning lights

What belongs here

Symptoms, known abnormal tests, clinician-requested follow-up

Why it comes first

Already abnormal beats speculative optimization

Examples

Chest pain, blood in stool, positive FIT, abnormal mammogram, rising creatinine, unexplained anemia

Priority tier

2. Fatal loops

What belongs here

Silent, common, preventable drivers of early morbidity and mortality

Why it comes first

High absolute risk + high actionability

Examples

Blood pressure, ApoB/LDL/Lp(a), metabolic risk, cancer screening, sleep apnea, kidney/liver risk

Priority tier

3. Asymmetric safeguards

What belongs here

Low-friction steps that prevent large downside

Why it comes first

Cheap, boring, often skipped

Examples

Tobacco/nicotine exposure, alcohol floor, seat belts, helmets, fall prevention, medication review, vaccines, aspirin review

Priority tier

4. Physiologic reserve

What belongs here

Capacity to tolerate illness, aging, travel, stress, and recovery

Why it comes first

Healthspan depends on reserve, not just absence of disease

Examples

Aerobic fitness, strength, balance, sleep, protein/fiber, hearing/vision, social connection

Priority tier

5. Advanced / personalized tools

What belongs here

Tests or interventions with context-dependent value

Why it comes first

Useful when they change a decision after the basics and follow-up plan are real

Examples

MCED, whole-body MRI, CGM, CAC, hormones, genomics, biological-age clocks, microbiome reports, supplements

How to use this guide without turning it into homework

Use the tables as anchors, not as a diagnosis engine. Some ranges are formal diagnostic cut points; others are practical decision thresholds or risk-enhancing signals. Targets can change with age, pregnancy history, kidney disease, diabetes, ASCVD risk, medications, symptoms, and personal tradeoffs.

The useful question is not “is this number perfect?” It is “does this result change what I do next?” If the answer is no, it may not deserve top billing.

Educational, not personal medical advice. If you have symptoms, a known abnormal result, or a clinician has asked you to repeat or follow up something, that outranks this guide.

Why most longevity checklists get the order wrong

A lot of longevity advice is organized by novelty. That is how people end up comparing epigenetic clocks while they do not know their home blood pressure, debating supplement stacks while colorectal screening is overdue, or wearing three devices while weekend alcohol is wrecking sleep, mood, reflux, and blood pressure.

The problem is not curiosity. The problem is sequence.

A useful audit uses this formula: priority = absolute risk × preventability × actionability × evidence quality × personalization.

That formula pushes boring, measurable, evidence-backed risks above shiny objects. It also keeps the audit personal. A 35-year-old cyclist with a strong family history of early heart disease should not have the same first five priorities as a 68-year-old with falls, insomnia, hypertension, and ten medications.

Where the hallmarks of aging fit

Mechanism-to-audit filter showing how hallmarks of aging become useful only when translated into human proxies, decision-changing metrics, and lower-harm actions.

Hallmarks explain the biology. The audit filter decides what belongs in care.

The hallmarks of aging are the mechanism map underneath the audit: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem-cell exhaustion, altered intercellular communication, chronic inflammation, and dysbiosis.

That biology matters because it explains why the “boring” levers are not boring. DNA damage, telomeres, and senescence point toward cancer risk, tobacco and UV exposure, infection prevention, and abnormal-test follow-through. Nutrient sensing, mitochondria, autophagy, and proteostasis point toward insulin resistance, visceral fat, fitness, muscle, sleep, protein, alcohol, and medication context. Inflammation, dysbiosis, altered signaling, and stem-cell exhaustion point toward sleep apnea, oral and infection risk, chronic inflammatory disease, fiber, frailty, bone, recovery, and immune vulnerability.

Mechanisms are useful when they translate into a human proxy, a decision-changing metric, and a lower-harm action. Otherwise they belong in the research file, not at the top of your weekend checklist.

First: symptoms are not audit items

This guide is for prevention and risk review in people who are generally stable. It is not a substitute for medical care.

If you have chest pain, shortness of breath out of proportion, fainting, new neurologic symptoms, a new severe headache, unexplained weight loss, blood in stool, persistent fevers, abnormal bleeding, new focal weakness, severe depression, suicidal thoughts, or another concerning symptom, do not turn it into a longevity project. Get evaluated.

Same for the things already trying to get your attention: a positive stool test, abnormal mammogram, persistently high blood pressure, rising creatinine, unexplained anemia, abnormal bleeding, or a lab your clinician asked you to repeat.

The first audit question is simple: is there already a warning light I am trying to rebrand as optimization? If yes, start there.

Tier 1: close the fatal loops

Checklist-style fatal-loop triage map for known abnormal results, cardiovascular risk, cancer screening, sleep apnea, kidney/liver risk, and targeted vascular screening.

If a fatal-risk loop is open, close that branch before adding optimization projects.

These are the risks and conditions that often kill early, silently, or preventably. They usually deserve attention before exotic optimization.

1. Blood pressure: the highest-ROI home metric

Blood pressure is common, silent, measurable, actionable, and easy to measure badly. It drives stroke, heart disease, heart failure, kidney disease, vascular brain injury, and pregnancy-related risk patterns.

The audit question is not “what was one clinic reading?” It is: do I know my usual home blood pressure, measured with the right cuff and technique, and do I have a plan if it is repeatedly high?

Protocol

Blood pressure ranges to know

Normal

Typical anchor: <120 systolic and <80 diastolic
What it means for the audit: Good baseline if measured correctly; still repeat over time
Next move: Keep a validated cuff, repeat periodically, protect sleep/activity/nutrition

Elevated

Typical anchor: 120–129 systolic and <80 diastolic
What it means for the audit: Early warning zone; do not wait until it is “real hypertension” to care
Next move: Standardize home readings, reduce sodium/alcohol if relevant, increase activity, recheck

Stage 1 hypertension

Typical anchor: 130–139 systolic or 80–89 diastolic
What it means for the audit: Risk context decides intensity; confirmation matters
Next move: Confirm with home/ambulatory readings and discuss ASCVD risk, lifestyle, and medication threshold

Stage 2 hypertension

Typical anchor: ≥140 systolic or ≥90 diastolic
What it means for the audit: High-priority fatal loop
Next move: Confirm promptly and create an actual treatment plan

Severe range

Typical anchor: >180 systolic and/or >120 diastolic
What it means for the audit: Not a longevity spreadsheet item
Next move: Repeat after 1 minute; if symptoms such as chest pain, shortness of breath, neurologic symptoms, vision change, weakness, or trouble speaking: call emergency services

Range	Typical anchor	What it means for the audit	Next move
Normal	<120 systolic and <80 diastolic	Good baseline if measured correctly; still repeat over time	Keep a validated cuff, repeat periodically, protect sleep/activity/nutrition
Elevated	120–129 systolic and <80 diastolic	Early warning zone; do not wait until it is “real hypertension” to care	Standardize home readings, reduce sodium/alcohol if relevant, increase activity, recheck
Stage 1 hypertension	130–139 systolic or 80–89 diastolic	Risk context decides intensity; confirmation matters	Confirm with home/ambulatory readings and discuss ASCVD risk, lifestyle, and medication threshold
Stage 2 hypertension	≥140 systolic or ≥90 diastolic	High-priority fatal loop	Confirm promptly and create an actual treatment plan
Severe range	>180 systolic and/or >120 diastolic	Not a longevity spreadsheet item	Repeat after 1 minute; if symptoms such as chest pain, shortness of breath, neurologic symptoms, vision change, weakness, or trouble speaking: call emergency services

If you buy only one home device, make it a validated upper-arm blood pressure cuff. Not sexy. Extremely useful. The cuff does not care about your supplement drawer.

2. Atherogenic lipoproteins: LDL-C, non-HDL-C, ApoB, and Lp(a)

The most common fatal surprise is often not a surprise biologically. It is years of blood pressure, ApoB-containing particles, glucose, inflammation, and family history adding up in the background.

Core questions: What are my LDL-C and non-HDL-C? Do I know ApoB if metabolic risk, high triglycerides, insulin resistance, or discordance is possible? Have I checked Lp(a) once in adulthood? Is there premature ASCVD, stroke, sudden death, or very high cholesterol in my family? Would CAC change a treatment decision, or am I ordering it to feel thorough?

Protocol

Cardiovascular lab anchors

LDL-C

Useful anchor: LDL-C ≥190 mg/dL is a major red flag; lower targets depend on total risk
Why it matters: LDL is a causal atherogenic exposure over time
What changes the plan: Very high LDL, premature family history, diabetes, CKD, high 10-year risk, or existing ASCVD shifts intensity

Non-HDL-C

Useful anchor: Useful when triglycerides are elevated or LDL alone may understate particle burden
Why it matters: Captures cholesterol carried by ApoB-containing particles
What changes the plan: Discordance with LDL-C can support checking ApoB and treating the risk stack, not the prettiest number

ApoB

Useful anchor: ApoB ≥130 mg/dL is often treated as a risk-enhancing signal; lower targets are risk-dependent
Why it matters: Counts atherogenic particles more directly than LDL-C
What changes the plan: Especially useful with insulin resistance, high triglycerides, obesity, diabetes risk, or LDL/ApoB discordance

Lp(a)

Useful anchor: Check once in adulthood; ≥50 mg/dL or ≥125 nmol/L is commonly used as elevated/risk-enhancing
Why it matters: Mostly genetic and can raise lifetime ASCVD/aortic-valve risk
What changes the plan: High Lp(a) usually means managing every modifiable risk factor more aggressively

CAC

Useful anchor: Most useful in selected borderline/intermediate-risk adults when statin decision is uncertain
Why it matters: Shows calcified coronary plaque burden, not total plaque or future immunity
What changes the plan: Use when it will change a decision; do not use as a universal reassurance scan

Signal	Useful anchor	Why it matters	What changes the plan
LDL-C	LDL-C ≥190 mg/dL is a major red flag; lower targets depend on total risk	LDL is a causal atherogenic exposure over time	Very high LDL, premature family history, diabetes, CKD, high 10-year risk, or existing ASCVD shifts intensity
Non-HDL-C	Useful when triglycerides are elevated or LDL alone may understate particle burden	Captures cholesterol carried by ApoB-containing particles	Discordance with LDL-C can support checking ApoB and treating the risk stack, not the prettiest number
ApoB	ApoB ≥130 mg/dL is often treated as a risk-enhancing signal; lower targets are risk-dependent	Counts atherogenic particles more directly than LDL-C	Especially useful with insulin resistance, high triglycerides, obesity, diabetes risk, or LDL/ApoB discordance
Lp(a)	Check once in adulthood; ≥50 mg/dL or ≥125 nmol/L is commonly used as elevated/risk-enhancing	Mostly genetic and can raise lifetime ASCVD/aortic-valve risk	High Lp(a) usually means managing every modifiable risk factor more aggressively
CAC	Most useful in selected borderline/intermediate-risk adults when statin decision is uncertain	Shows calcified coronary plaque burden, not total plaque or future immunity	Use when it will change a decision; do not use as a universal reassurance scan

Lp(a) is mostly genetic. A high value can change how aggressively the rest of the risk stack should be managed. CAC can help selected adults when the statin decision is uncertain. It is not a moral verdict on your arteries.

3. Metabolic risk: glucose, waist, liver, kidney, and insulin-resistance context

Metabolic risk affects cardiovascular disease, kidney disease, fatty liver, sleep apnea, neuropathy, infections, cancer risk patterns, and cognitive aging.

The minimum audit usually includes A1c and/or fasting glucose by age/risk, waist or another visceral-fat proxy when useful, blood pressure, lipids, triglycerides, HDL-C, liver enzymes, and kidney markers when context supports them.

Protocol

Metabolic and organ-risk anchors

A1c

Typical range or trigger: Normal <5.7%; prediabetes 5.7–6.4%; diabetes ≥6.5%
What it catches: Average glycemia over roughly 2–3 months; imperfect with anemia, hemoglobin variants, pregnancy, CKD, and some ethnic/genetic contexts
Next move: If prediabetes or diabetes range, confirm and build a plan; do not “watch” it for years without intervention

Fasting glucose

Typical range or trigger: Normal <100 mg/dL; impaired fasting glucose 100–125; diabetes-range ≥126
What it catches: Fasting hepatic glucose output and insulin-resistance context
Next move: Repeat/confirm abnormal results; pair with A1c, triglycerides, waist, BP, and family history

Triglycerides / HDL-C

Typical range or trigger: TG ≥150 mg/dL is a common risk flag; low HDL is context, not a drug target by itself
What it catches: Often tracks insulin resistance, alcohol effect, thyroid, genetics, medications, and liver fat
Next move: Look for the pattern: waist, A1c/glucose, ApoB, alcohol, diet quality, sleep apnea, liver enzymes

Waist circumference

Typical range or trigger: >35 in women or >40 in men is a traditional cardiometabolic-risk threshold; ethnicity-specific thresholds may be lower
What it catches: Visceral adiposity proxy; more informative than BMI alone for many people
Next move: Measure consistently; use it with labs and blood pressure, not as a shame metric

Liver enzymes / fatty liver context

Typical range or trigger: Persistent ALT/AST elevation, metabolic risk, alcohol, viral hepatitis risk, or steatotic liver disease history
What it catches: Liver disease can be silent until late
Next move: Review alcohol, metabolic risk, medications/supplements, hepatitis testing, fibrosis risk, and imaging only when useful

Kidney markers

Typical range or trigger: Creatinine/eGFR plus urine albumin-creatinine ratio in higher-risk people
What it catches: Kidney risk is easy to miss if you only look at creatinine
Next move: Prioritize if diabetes, hypertension, ASCVD, autoimmune disease, family history, pregnancy complications, or nephrotoxic medication exposure

Signal	Typical range or trigger	What it catches	Next move
A1c	Normal <5.7%; prediabetes 5.7–6.4%; diabetes ≥6.5%	Average glycemia over roughly 2–3 months; imperfect with anemia, hemoglobin variants, pregnancy, CKD, and some ethnic/genetic contexts	If prediabetes or diabetes range, confirm and build a plan; do not “watch” it for years without intervention
Fasting glucose	Normal <100 mg/dL; impaired fasting glucose 100–125; diabetes-range ≥126	Fasting hepatic glucose output and insulin-resistance context	Repeat/confirm abnormal results; pair with A1c, triglycerides, waist, BP, and family history
Triglycerides / HDL-C	TG ≥150 mg/dL is a common risk flag; low HDL is context, not a drug target by itself	Often tracks insulin resistance, alcohol effect, thyroid, genetics, medications, and liver fat	Look for the pattern: waist, A1c/glucose, ApoB, alcohol, diet quality, sleep apnea, liver enzymes
Waist circumference	>35 in women or >40 in men is a traditional cardiometabolic-risk threshold; ethnicity-specific thresholds may be lower	Visceral adiposity proxy; more informative than BMI alone for many people	Measure consistently; use it with labs and blood pressure, not as a shame metric
Liver enzymes / fatty liver context	Persistent ALT/AST elevation, metabolic risk, alcohol, viral hepatitis risk, or steatotic liver disease history	Liver disease can be silent until late	Review alcohol, metabolic risk, medications/supplements, hepatitis testing, fibrosis risk, and imaging only when useful
Kidney markers	Creatinine/eGFR plus urine albumin-creatinine ratio in higher-risk people	Kidney risk is easy to miss if you only look at creatinine	Prioritize if diabetes, hypertension, ASCVD, autoimmune disease, family history, pregnancy complications, or nephrotoxic medication exposure

The USPSTF recommends screening adults 35 to 70 with overweight or obesity for prediabetes and type 2 diabetes, with individualized earlier screening for higher-risk histories. If prediabetes is found, it is not a shrug: the Diabetes Prevention Program showed intensive lifestyle intervention reduced diabetes incidence by 58 percent compared with placebo over about 2.8 years, with metformin reducing incidence by 31 percent.

4. Cancer and preventive screening: right test, right person, right interval

Cancer screening is not “scan everything and hope.” It is the right test, for the right risk, at the right interval, with a plan for what happens if the result is abnormal. That includes standard screening first, and it can include emerging tools when the consent and follow-up plan are mature enough.

Protocol

Screening loops most adults should audit

Colorectal cancer

Common evidence-based anchor: Average-risk adults generally start at 45; routine screening usually through 75
Who needs personalization: Family history, prior polyps, inflammatory bowel disease, hereditary syndromes, symptoms
Open-loop question: Am I up to date, and if I used stool testing, was any positive result followed by colonoscopy?

Breast cancer

Common evidence-based anchor: USPSTF: mammogram every 2 years from 40 to 74 for average-risk women
Who needs personalization: Dense breasts, prior atypia, chest radiation, strong family history, BRCA/Lynch-related patterns
Open-loop question: Is my interval/risk category explicit rather than inherited from a generic reminder?

Cervical cancer

Common evidence-based anchor: Age 21–65 using cytology/HPV strategy by age and history
Who needs personalization: Prior abnormal results, immunosuppression, DES exposure, hysterectomy details
Open-loop question: Do I know my last Pap/HPV result and the actual follow-up interval?

Lung cancer

Common evidence-based anchor: Annual low-dose CT for adults 50–80 with ≥20 pack-years who currently smoke or quit within 15 years
Who needs personalization: Occupational exposures, symptoms, prior nodules, comorbidities that affect treatment candidacy
Open-loop question: If I qualify, am I in a structured screening program with follow-up?

Prostate cancer

Common evidence-based anchor: Shared decision-making is commonly emphasized for men 55–69
Who needs personalization: Black ancestry, strong family history, BRCA2 or other hereditary risk, urinary symptoms
Open-loop question: Was PSA ordered as a decision or as a reflex? What would we do with the result?

Skin cancer

Common evidence-based anchor: Risk-based skin exams rather than universal population screening
Who needs personalization: Personal or family history, many atypical nevi, immunosuppression, high UV exposure, prior skin cancer
Open-loop question: Should I have a dermatologist skin check interval, and do I know what changes should trigger a visit?

MCED blood tests

Common evidence-based anchor: Emerging and promising; not a replacement for standard screening or a proven mortality-reduction tool yet
Who needs personalization: Best considered when the person understands false positives, false negatives, uncertain benefit, follow-up testing, cost, and anxiety burden
Open-loop question: Would this result change my plan, and do we have a concrete diagnostic pathway if it is positive?

Whole-body MRI

Common evidence-based anchor: Emerging adjunct for selected, well-counseled people; especially different from casual “scan everything” marketing
Who needs personalization: Can detect some unexpected findings without radiation, but incidental findings and follow-up cascades are common and mortality benefit is unproven
Open-loop question: Who reads it, what protocol is used, what findings will we ignore, and who owns follow-up?

Hepatitis C

Common evidence-based anchor: USPSTF: adults 18–79; CDC: all adults at least once, plus each pregnancy and periodic testing for ongoing risk
Who needs personalization: Injection drug use, HIV, dialysis, abnormal liver tests, transfusion before 1992
Open-loop question: Was a positive antibody followed by RNA testing?

AAA

Common evidence-based anchor: One-time ultrasound for men 65–75 who have ever smoked; selective decisions for others
Who needs personalization: Family history, connective-tissue disease, sex-specific uncertainty
Open-loop question: Do I actually meet criteria, or am I imaging because “more screening” feels safer?

Osteoporosis

Common evidence-based anchor: Women ≥65 and younger postmenopausal women at increased risk
Who needs personalization: Steroids, early menopause, low-trauma fracture, low BMI, parental hip fracture, aromatase inhibitors, malabsorption
Open-loop question: Am I evaluating fracture risk, not just admiring a body-composition DXA?

Screening area	Common evidence-based anchor	Who needs personalization	Open-loop question
Colorectal cancer	Average-risk adults generally start at 45; routine screening usually through 75	Family history, prior polyps, inflammatory bowel disease, hereditary syndromes, symptoms	Am I up to date, and if I used stool testing, was any positive result followed by colonoscopy?
Breast cancer	USPSTF: mammogram every 2 years from 40 to 74 for average-risk women	Dense breasts, prior atypia, chest radiation, strong family history, BRCA/Lynch-related patterns	Is my interval/risk category explicit rather than inherited from a generic reminder?
Cervical cancer	Age 21–65 using cytology/HPV strategy by age and history	Prior abnormal results, immunosuppression, DES exposure, hysterectomy details	Do I know my last Pap/HPV result and the actual follow-up interval?
Lung cancer	Annual low-dose CT for adults 50–80 with ≥20 pack-years who currently smoke or quit within 15 years	Occupational exposures, symptoms, prior nodules, comorbidities that affect treatment candidacy	If I qualify, am I in a structured screening program with follow-up?
Prostate cancer	Shared decision-making is commonly emphasized for men 55–69	Black ancestry, strong family history, BRCA2 or other hereditary risk, urinary symptoms	Was PSA ordered as a decision or as a reflex? What would we do with the result?
Skin cancer	Risk-based skin exams rather than universal population screening	Personal or family history, many atypical nevi, immunosuppression, high UV exposure, prior skin cancer	Should I have a dermatologist skin check interval, and do I know what changes should trigger a visit?
MCED blood tests	Emerging and promising; not a replacement for standard screening or a proven mortality-reduction tool yet	Best considered when the person understands false positives, false negatives, uncertain benefit, follow-up testing, cost, and anxiety burden	Would this result change my plan, and do we have a concrete diagnostic pathway if it is positive?
Whole-body MRI	Emerging adjunct for selected, well-counseled people; especially different from casual “scan everything” marketing	Can detect some unexpected findings without radiation, but incidental findings and follow-up cascades are common and mortality benefit is unproven	Who reads it, what protocol is used, what findings will we ignore, and who owns follow-up?
Hepatitis C	USPSTF: adults 18–79; CDC: all adults at least once, plus each pregnancy and periodic testing for ongoing risk	Injection drug use, HIV, dialysis, abnormal liver tests, transfusion before 1992	Was a positive antibody followed by RNA testing?
AAA	One-time ultrasound for men 65–75 who have ever smoked; selective decisions for others	Family history, connective-tissue disease, sex-specific uncertainty	Do I actually meet criteria, or am I imaging because “more screening” feels safer?
Osteoporosis	Women ≥65 and younger postmenopausal women at increased risk	Steroids, early menopause, low-trauma fracture, low BMI, parental hip fracture, aromatase inhibitors, malabsorption	Am I evaluating fracture risk, not just admiring a body-composition DXA?

The point is screening with follow-through. MCED blood tests and whole-body MRI are emerging and promising, and I think they can be worth doing for the right person. But they are not magic shields or replacements for colonoscopy, mammography, cervical screening, lung screening when eligible, or risk-based workups. The consent has to be honest: false positives, false negatives, incidental findings, downstream imaging/biopsy, anxiety, cost, insurance friction, and still-uncertain mortality benefit.

5. Sleep apnea: do not normalize low oxygen and broken sleep

Sleep apnea is a fatal-loop issue when the history fits: loud snoring, witnessed apneas, morning headaches, resistant hypertension, atrial fibrillation, unexplained fatigue, reflux, nocturia, or high-risk anatomy. It affects blood pressure, arrhythmia risk, metabolic control, mood, cognition, and accident risk.

The audit question is not “am I tired?” It is “is my sleep fragmenting my physiology enough that testing and treatment would change the plan?” Home sleep apnea testing or polysomnography belongs here when the pre-test probability is real.

6. Kidney, liver, and selective vascular screening

Kidney and liver disease often sit behind more glamorous risks. For kidney risk, the basics are creatinine/eGFR and urine albumin-creatinine ratio in people with diabetes, hypertension, cardiovascular disease, prior abnormal kidney labs, family history, pregnancy complications, autoimmune disease, or nephrotoxic medication exposure.

For liver risk, ask about alcohol, metabolic risk, viral hepatitis, medications, supplements, and persistent liver enzyme abnormalities. For aneurysms, be targeted: AAA ultrasound where indicated, and brain aneurysm screening only in high-risk contexts such as multiple affected first-degree relatives, ADPKD, or selected genetic syndromes.

A good audit is not “image everything.” It is “screen where finding something is likely to help, and use broader tools only when the person understands what may happen next.”

Tier 2: remove asymmetric risks

Asymmetric-risk matrix for low-friction safeguards including tobacco and nicotine exposure, alcohol, falls, medication review, vaccines, and informed-consent tools such as MCED and whole-body MRI.

Low-friction safeguards can outrank glamorous optimization when the downside prevented is large.

Some risks are obvious enough that longevity people skip them. That is a mistake. This is where tobacco/nicotine exposure belongs: not because it is small, but because the intervention logic is asymmetric.

Tobacco, nicotine, and smoke exposure

Combustible tobacco is one of the clearest asymmetric risks in medicine: huge downside, strong evidence, and a concrete first decision—get exposure to zero with real support. Vaping, nicotine pouches, and secondhand smoke are not identical to cigarettes, but they still belong in the audit because they can reinforce dependence, affect blood pressure and sleep, and change lung-screening or vascular-risk context.

This should not be handled as a moral lecture or a checkbox. It should be handled as a system: identify the exposure, reduce friction, use evidence-based cessation tools when needed, and make sure anyone who qualifies for lung cancer screening is actually in a structured follow-up pathway.

Protocol

Asymmetric risk anchors

Tobacco / nicotine exposure

Anchor: Combustible tobacco: get to zero. Vaping, pouches, and secondhand smoke still belong in the audit because dependence, BP/sympathetic tone, sleep, anxiety, and lung-screening eligibility can matter.
Why it matters: Very large downside relative to the first decision: identify exposure, reduce friction, and use evidence-based support rather than willpower theater.
Audit move: Ask about smoking, vaping, nicotine pouches, secondhand exposure, cessation meds/coaching, and whether lung cancer screening criteria are met.

Alcohol

Anchor: Binge drinking: ≥4 drinks for women or ≥5 for men on an occasion. Heavy drinking: ≥8 drinks/week for women or ≥15 for men.
Why it matters: Alcohol worsens sleep, BP, AFib risk, liver disease, injury risk, reflux, mood, cancer risk, cravings, and medication interactions.
Audit move: Track actual weekly pattern and run a lower-intake experiment if sleep, BP, HRV/RHR, mood, reflux, or cravings worsen after drinking.

Seat belts

Anchor: Front-seat belts cut fatal-injury risk roughly in half in passenger vehicles.
Why it matters: A one-second habit prevents a catastrophic tail risk.
Audit move: Every trip, every seat; especially taxis/rideshare/late nights.

Helmets / exposure safety

Anchor: Risk depends on actual exposure: bikes, e-bikes, skiing, motorcycles, climbing, commuting while sleep-deprived.
Why it matters: Asymmetric risk math beats aesthetic objections.
Audit move: Match the safeguard to the activity you actually do.

Falls and fractures

Anchor: Adults ≥65 at increased fall risk benefit from exercise interventions; osteoporosis screening matters by age/risk.
Why it matters: Falls can collapse independence quickly.
Audit move: Review falls/near-falls, balance, vision/hearing, sedating meds, footwear, strength, and DXA/fracture-risk context.

Medication burden

Anchor: Benzodiazepines, Z-drugs, opioids, gabapentinoids, anticholinergics, NSAIDs, PPIs, duplicates, and supplements can add hidden risk.
Why it matters: Side effects masquerade as aging.
Audit move: Bring the real list, including supplements, and ask what can be simplified safely.

Vaccines

Anchor: CDC adult schedule changes by age, risk, pregnancy, immune status, and prior doses.
Why it matters: Low-drama prevention for high-cost infections.
Audit move: Audit flu, COVID, Tdap/Td, shingles, pneumococcal, RSV, hepatitis B, travel, and risk-based vaccines.

Aspirin

Anchor: USPSTF: individual decision age 40–59 with ≥10% 10-year CVD risk; do not initiate for primary prevention at ≥60.
Why it matters: Prevention can harm when bleeding risk exceeds benefit.
Audit move: Do not start or stop casually; review indication, age, bleeding risk, and CVD risk with a clinician.

Area	Anchor	Why it matters	Audit move
Tobacco / nicotine exposure	Combustible tobacco: get to zero. Vaping, pouches, and secondhand smoke still belong in the audit because dependence, BP/sympathetic tone, sleep, anxiety, and lung-screening eligibility can matter.	Very large downside relative to the first decision: identify exposure, reduce friction, and use evidence-based support rather than willpower theater.	Ask about smoking, vaping, nicotine pouches, secondhand exposure, cessation meds/coaching, and whether lung cancer screening criteria are met.
Alcohol	Binge drinking: ≥4 drinks for women or ≥5 for men on an occasion. Heavy drinking: ≥8 drinks/week for women or ≥15 for men.	Alcohol worsens sleep, BP, AFib risk, liver disease, injury risk, reflux, mood, cancer risk, cravings, and medication interactions.	Track actual weekly pattern and run a lower-intake experiment if sleep, BP, HRV/RHR, mood, reflux, or cravings worsen after drinking.
Seat belts	Front-seat belts cut fatal-injury risk roughly in half in passenger vehicles.	A one-second habit prevents a catastrophic tail risk.	Every trip, every seat; especially taxis/rideshare/late nights.
Helmets / exposure safety	Risk depends on actual exposure: bikes, e-bikes, skiing, motorcycles, climbing, commuting while sleep-deprived.	Asymmetric risk math beats aesthetic objections.	Match the safeguard to the activity you actually do.
Falls and fractures	Adults ≥65 at increased fall risk benefit from exercise interventions; osteoporosis screening matters by age/risk.	Falls can collapse independence quickly.	Review falls/near-falls, balance, vision/hearing, sedating meds, footwear, strength, and DXA/fracture-risk context.
Medication burden	Benzodiazepines, Z-drugs, opioids, gabapentinoids, anticholinergics, NSAIDs, PPIs, duplicates, and supplements can add hidden risk.	Side effects masquerade as aging.	Bring the real list, including supplements, and ask what can be simplified safely.
Vaccines	CDC adult schedule changes by age, risk, pregnancy, immune status, and prior doses.	Low-drama prevention for high-cost infections.	Audit flu, COVID, Tdap/Td, shingles, pneumococcal, RSV, hepatitis B, travel, and risk-based vaccines.
Aspirin	USPSTF: individual decision age 40–59 with ≥10% 10-year CVD risk; do not initiate for primary prevention at ≥60.	Prevention can harm when bleeding risk exceeds benefit.	Do not start or stop casually; review indication, age, bleeding risk, and CVD risk with a clinician.

Alcohol is not a longevity supplement with a branding problem. Tobacco and nicotine exposure do not become harmless because the delivery device looks modern. Seat belts and helmets are not wellness content, but they may beat half the supplement aisle on downside prevented.

Tier 3: build physiologic reserve

Physiologic reserve dashboard with a radar chart for aerobic capacity, strength, balance, sleep, nutrition, metabolic health, cognition, and social connection.

Healthspan work becomes personal when the weakest spoke chooses the next move.

Closing fatal loops helps you avoid preventable disease. Building reserve helps you stay functional when life happens.

Protocol

Physiologic reserve targets

Cardiorespiratory fitness

Practical anchor: At least 150 min/week moderate activity, 75 min/week vigorous, or a mix; more helps if recovered well
What it tells you: Integrates heart, lungs, vessels, muscle, mitochondria, autonomic tone, and behavior
First move: Build a floor first: walking, cycling, incline, zone 2-ish work, then safe intensity if appropriate

Strength

Practical anchor: Muscle-strengthening activity at least 2 days/week, all major muscle groups
What it tells you: Predicts function: stairs, luggage, illness recovery, falls, independence
First move: Two full-body sessions beat a perfect plan you never start

Balance / power

Practical anchor: Especially important with age, falls, vestibular issues, neuropathy, sedating meds, or low activity
What it tells you: Fall risk is often trainable
First move: Single-leg stance, sit-to-stand, carries, stepping, supervised balance/physical therapy if risk is high

Nutrition

Practical anchor: Fiber around 25–29 g/day is a useful evidence-backed anchor; protein depends on age, training, weight loss, and frailty risk
What it tells you: Diet should move physiology: ApoB, BP, A1c, liver enzymes, waist, satiety, digestion, muscle
First move: Add fiber/protein before adding rules; use labs and function as feedback

Sleep

Practical anchor: Adults generally need 7+ hours; 61–64: 7–9; 65+: 7–8 is a common range
What it tells you: Sleep affects BP, glycemia, appetite, mood, cognition, pain, injury risk, and recovery
First move: Protect schedule and screen for apnea symptoms: snoring, witnessed apneas, gasping, morning headaches, sleepiness, resistant hypertension, AFib

Social / sensory

Practical anchor: Recurring contact, hearing and vision correction when needed, crisis support
What it tells you: Isolation, hearing loss, vision loss, depression, and caregiver strain can become health risks
First move: Make it operational: who, when, how often, and what ritual keeps it alive

Domain	Practical anchor	What it tells you	First move
Cardiorespiratory fitness	At least 150 min/week moderate activity, 75 min/week vigorous, or a mix; more helps if recovered well	Integrates heart, lungs, vessels, muscle, mitochondria, autonomic tone, and behavior	Build a floor first: walking, cycling, incline, zone 2-ish work, then safe intensity if appropriate
Strength	Muscle-strengthening activity at least 2 days/week, all major muscle groups	Predicts function: stairs, luggage, illness recovery, falls, independence	Two full-body sessions beat a perfect plan you never start
Balance / power	Especially important with age, falls, vestibular issues, neuropathy, sedating meds, or low activity	Fall risk is often trainable	Single-leg stance, sit-to-stand, carries, stepping, supervised balance/physical therapy if risk is high
Nutrition	Fiber around 25–29 g/day is a useful evidence-backed anchor; protein depends on age, training, weight loss, and frailty risk	Diet should move physiology: ApoB, BP, A1c, liver enzymes, waist, satiety, digestion, muscle	Add fiber/protein before adding rules; use labs and function as feedback
Sleep	Adults generally need 7+ hours; 61–64: 7–9; 65+: 7–8 is a common range	Sleep affects BP, glycemia, appetite, mood, cognition, pain, injury risk, and recovery	Protect schedule and screen for apnea symptoms: snoring, witnessed apneas, gasping, morning headaches, sleepiness, resistant hypertension, AFib
Social / sensory	Recurring contact, hearing and vision correction when needed, crisis support	Isolation, hearing loss, vision loss, depression, and caregiver strain can become health risks	Make it operational: who, when, how often, and what ritual keeps it alive

If I could only know one “longevity lab” about someone, I would rather know how much work their body can do than how many supplements they take.

Hormone health belongs, but not as a generic panel

Hormones belong in a longevity audit because transitions can change sleep, mood, bone, muscle, sexual function, fertility, cardiometabolic risk, and day-to-day function. They do not belong as a generic “optimize your hormones” panel for everyone with a credit card.

Protocol

When hormones become audit-relevant

Menstrual / reproductive

What to look for: Irregular cycles, amenorrhea, heavy bleeding, infertility, PCOS, hyperandrogenic symptoms, low-energy availability
Why it matters: Can signal endocrine, metabolic, bone, or fertility issues
Caution: Do not reduce it to a random day-3 panel without a question

Pregnancy history

What to look for: Gestational diabetes, preeclampsia, gestational hypertension, preterm birth, recurrent pregnancy loss
Why it matters: Changes long-term cardiometabolic risk assessment
Caution: Pregnancy complications are not “old history” for prevention

Perimenopause / menopause

What to look for: Vasomotor symptoms, sleep disruption, genitourinary symptoms, early menopause/POI, surgical menopause, bone risk, abnormal bleeding
Why it matters: Symptoms, bone, cardiometabolic shifts, and quality of life may change the plan
Caution: MHT can be appropriate for symptoms/risk context, but not generic chronic-disease prevention

Testosterone in men

What to look for: Low libido, erectile dysfunction, unexplained anemia, low bone density, infertility concerns, loss of muscle/strength in context
Why it matters: Diagnosis requires symptoms/signs plus consistently low morning testosterone
Caution: One curiosity lab is not a diagnosis

Thyroid

What to look for: Palpitations, tremor, heat/cold intolerance, constipation, unexplained weight change, goiter, autoimmune history, lithium/amiodarone
Why it matters: Thyroid disease can mimic many “optimization” complaints
Caution: Routine asymptomatic screening is not always high-yield; symptoms/risk matter

Context	What to look for	Why it matters	Caution
Menstrual / reproductive	Irregular cycles, amenorrhea, heavy bleeding, infertility, PCOS, hyperandrogenic symptoms, low-energy availability	Can signal endocrine, metabolic, bone, or fertility issues	Do not reduce it to a random day-3 panel without a question
Pregnancy history	Gestational diabetes, preeclampsia, gestational hypertension, preterm birth, recurrent pregnancy loss	Changes long-term cardiometabolic risk assessment	Pregnancy complications are not “old history” for prevention
Perimenopause / menopause	Vasomotor symptoms, sleep disruption, genitourinary symptoms, early menopause/POI, surgical menopause, bone risk, abnormal bleeding	Symptoms, bone, cardiometabolic shifts, and quality of life may change the plan	MHT can be appropriate for symptoms/risk context, but not generic chronic-disease prevention
Testosterone in men	Low libido, erectile dysfunction, unexplained anemia, low bone density, infertility concerns, loss of muscle/strength in context	Diagnosis requires symptoms/signs plus consistently low morning testosterone	One curiosity lab is not a diagnosis
Thyroid	Palpitations, tremor, heat/cold intolerance, constipation, unexplained weight change, goiter, autoimmune history, lithium/amiodarone	Thyroid disease can mimic many “optimization” complaints	Routine asymptomatic screening is not always high-yield; symptoms/risk matter

Menopausal hormone therapy can be appropriate for symptoms and selected risk contexts, especially near menopause, but it should not be sold as generic chronic-disease prevention. Testosterone diagnosis requires compatible symptoms or signs plus consistently low morning testosterone, not one curiosity lab.

Biomarkers and wearables: use the actionability filter

Actionability gate for deciding whether a biomarker, wearable, supplement, or test should be added based on decision change, measurement quality, safe next action, and follow-up burden.

A biomarker earns its place only when it changes the next decision.

The best biomarker is not the most obscure one. It is the one that changes the next decision.

Protocol

Actionability filter for tests and trackers

If abnormal, what would I do?

Good answer: A specific next step: repeat, treat, refer, change behavior, change medication, or stop an exposure
Weak answer: I would worry more or buy more tests
Decision: Order only if the next step is clear enough

If normal, what would I stop doing?

Good answer: It would safely avoid a medication, scan, referral, or repeated monitoring
Weak answer: I would still keep checking it
Decision: Normal results should reduce noise, not add another dashboard

Is the measurement reliable?

Good answer: Validated method, standardized conditions, known limitations
Weak answer: Consumer score with unclear validity
Decision: Trend only what deserves a trend

Could it cause harm?

Good answer: False positives/negatives and incidental findings are understood
Weak answer: More data is assumed to be safer
Decision: Include cascade risk in the decision

Will tracking improve behavior?

Good answer: It changes sleep, activity, nutrition, medication adherence, or follow-up
Weak answer: It makes me more obsessive without changing the plan
Decision: Actionability beats curiosity

Question	Good answer	Weak answer	Decision
If abnormal, what would I do?	A specific next step: repeat, treat, refer, change behavior, change medication, or stop an exposure	I would worry more or buy more tests	Order only if the next step is clear enough
If normal, what would I stop doing?	It would safely avoid a medication, scan, referral, or repeated monitoring	I would still keep checking it	Normal results should reduce noise, not add another dashboard
Is the measurement reliable?	Validated method, standardized conditions, known limitations	Consumer score with unclear validity	Trend only what deserves a trend
Could it cause harm?	False positives/negatives and incidental findings are understood	More data is assumed to be safer	Include cascade risk in the decision
Will tracking improve behavior?	It changes sleep, activity, nutrition, medication adherence, or follow-up	It makes me more obsessive without changing the plan	Actionability beats curiosity

High-yield measurements usually include home blood pressure, LDL-C/non-HDL-C/ApoB, Lp(a) once, A1c or fasting glucose by age/risk, waist or body composition when management-changing, eGFR/uACR in higher-risk people, liver enzymes when alcohol/metabolic/medication context supports it, and CBC/ferritin/B12/TSH/vitamin D only when symptoms or risk make them actionable.

Wearables can help with trends: steps, activity minutes, resting heart rate, estimated fitness, sleep duration, sleep regularity, and HRV as a within-person recovery signal. CGM is high-value for diabetes and selected prediabetes, hypoglycemia, or short experiments; it is not a prerequisite before blood pressure, lipids, activity, strength, nutrition, and sleep. Normal wearable data does not rule out disease.

How to personalize the audit

The same checklist should not produce the same order for everyone.

Protocol

Personalization map by age and risk

20s–30s

What usually moves up: Baseline BP, lipids, Lp(a), family history, tobacco/alcohol exposure, fitness, sleep, vaccines, mental health, reproductive goals, high-exposure risks
What not to miss: Premature ASCVD family history, very high LDL, PCOS, pregnancy plans, biking/driving/sport risk, shift work

40s

What usually moves up: Colorectal screening at 45, breast/cervical screening by risk, ASCVD risk, ApoB/Lp(a), metabolic risk, perimenopause, body composition, sleep, selective CAC decisions
What not to miss: Blood pressure drift, insulin resistance, alcohol pattern, family cancer syndromes

50s–60s

What usually moves up: Lung screening if eligible, prostate shared decision-making, menopause, testosterone symptoms, bone density, sleep apnea, vaccines, alcohol, strength, balance
What not to miss: Medication burden, falls, hearing/vision, kidney/liver risk, high-risk family history

65+

What usually moves up: Falls, fractures, medication review, hearing, vision, vaccines, frailty, functional strength, cognition, social support, AAA where indicated
What not to miss: Sedatives/anticholinergics, isolation, gait change, undernutrition, osteoporosis

Family / reproductive history

What usually moves up: Premature ASCVD, sudden death, early cancer, Lynch/BRCA patterns, aneurysm, ADPKD, dementia, familial hypercholesterolemia, high Lp(a), preeclampsia, gestational diabetes, PCOS, early menopause
What not to miss: These can change the order more than age alone

Context	What usually moves up	What not to miss
20s–30s	Baseline BP, lipids, Lp(a), family history, tobacco/alcohol exposure, fitness, sleep, vaccines, mental health, reproductive goals, high-exposure risks	Premature ASCVD family history, very high LDL, PCOS, pregnancy plans, biking/driving/sport risk, shift work
40s	Colorectal screening at 45, breast/cervical screening by risk, ASCVD risk, ApoB/Lp(a), metabolic risk, perimenopause, body composition, sleep, selective CAC decisions	Blood pressure drift, insulin resistance, alcohol pattern, family cancer syndromes
50s–60s	Lung screening if eligible, prostate shared decision-making, menopause, testosterone symptoms, bone density, sleep apnea, vaccines, alcohol, strength, balance	Medication burden, falls, hearing/vision, kidney/liver risk, high-risk family history
65+	Falls, fractures, medication review, hearing, vision, vaccines, frailty, functional strength, cognition, social support, AAA where indicated	Sedatives/anticholinergics, isolation, gait change, undernutrition, osteoporosis
Family / reproductive history	Premature ASCVD, sudden death, early cancer, Lynch/BRCA patterns, aneurysm, ADPKD, dementia, familial hypercholesterolemia, high Lp(a), preeclampsia, gestational diabetes, PCOS, early menopause	These can change the order more than age alone

The point is not to build a larger checklist. It is to put the right thing first for the person in front of you.

A simple 30-day longevity audit

Do not overhaul your entire life in one weekend. That is how you create a spreadsheet and then avoid it forever.

Protocol

30-day audit plan

Week 1

Job: Collect the facts
Concrete output: Home BP average, medication/supplement list, recent lipids/ApoB/Lp(a), A1c/glucose, screening dates, vaccines, smoking/alcohol, sleep, steps/exercise, strength, falls history, family history

Week 2

Job: Close overdue loops
Concrete output: Schedule overdue screening, follow up abnormal results, confirm high BP properly, ask whether ApoB, Lp(a), CAC, uACR, DXA, HCV, or genetic counseling would change the plan

Week 3

Job: Install two behaviors
Concrete output: Validated BP tracking, two resistance sessions, higher fiber, a higher step floor, a lower-alcohol experiment, a consistent sleep window, or hearing/vision/fall-risk evaluation if relevant

Week 4

Job: Run one experiment
Concrete output: One question, one intervention, one metric, one decision. Good: increase fiber from 12 to 28 g/day for 8 weeks. Bad: start 12 supplements and see if you feel optimized.

Week	Job	Concrete output
Week 1	Collect the facts	Home BP average, medication/supplement list, recent lipids/ApoB/Lp(a), A1c/glucose, screening dates, vaccines, smoking/alcohol, sleep, steps/exercise, strength, falls history, family history
Week 2	Close overdue loops	Schedule overdue screening, follow up abnormal results, confirm high BP properly, ask whether ApoB, Lp(a), CAC, uACR, DXA, HCV, or genetic counseling would change the plan
Week 3	Install two behaviors	Validated BP tracking, two resistance sessions, higher fiber, a higher step floor, a lower-alcohol experiment, a consistent sleep window, or hearing/vision/fall-risk evaluation if relevant
Week 4	Run one experiment	One question, one intervention, one metric, one decision. Good: increase fiber from 12 to 28 g/day for 8 weeks. Bad: start 12 supplements and see if you feel optimized.

What not to chase first

Lower priority does not mean never. It means not first.

Whole-body MRI with no pre-test counseling, no radiology quality standard, and no follow-up plan.
Broad tumor-marker panels marketed as a shortcut. MCED is different and promising, but still emerging and not a replacement for standard screening.
Biological-age clocks.
Generic hormone panels without symptoms or risk context.
Microbiome reports that do not change the plan.
CGM for metabolically healthy people before basics are handled.
CAC as a universal scan.
Brain aneurysm screening without high-risk context.
Supplement stacks before BP, lipids, tobacco/nicotine exposure, alcohol, sleep, strength, and screening.

A good audit is not ascetic. It is ordered.

What to ask your clinician

Bring this as a starter list:

What is my highest-priority preventable risk right now?
Is my blood pressure actually controlled based on home or ambulatory data?
Do my lipids, ApoB, Lp(a), family history, or risk enhancers change my ASCVD plan?
Am I due for colorectal, breast, cervical, lung, prostate, skin, AAA, HCV, or osteoporosis screening based on my age and risk—and would MCED or whole-body MRI add useful information for me specifically?

If I choose MCED or whole-body MRI, what exactly would we do with a positive, negative, or indeterminate result?

Do my pregnancy history, PCOS, menopause status, testosterone symptoms, thyroid symptoms, or bone risk change what we should check?
Do any medications or supplements increase my falls, bleeding, kidney, liver, cognition, or sleep risk?
Which vaccines am I due for under current CDC guidance?
What result would change management, and what would we do if it is abnormal?

That last question may be the most important one.

Dr. Hillary Lin’s take

Longevity is not doing everything. It is doing the highest-leverage thing in the right order.

I am not against advanced testing. I am more open than many standard checklists to MCED blood tests and whole-body MRI for the right person, because early detection can matter. But I am against pretending they are magic. They need informed consent, a clean follow-up pathway, and the basics handled first.

The boring loops are boring because they have enough evidence to deserve priority. The emerging tools are interesting because they may catch what routine screening misses. Both can be true.

Close warning lights first. Use standard screening, asymmetric safeguards, and reserve-building as the base. Then add advanced tools when the result would actually change the next decision.

Clinical lens

How I’d decide

Use this section as a second pass after the main answer, not as homework before you know what the page is saying.

Who it’s for

Adults who want a practical prevention-first review of longevity risk: especially if they have not recently checked home blood pressure, ApoB/LDL/Lp(a), metabolic risk, cancer screening status, vaccines, alcohol pattern, sleep, fitness, medications, or family-history risk.

Who should skip it

Do not use this as a substitute for evaluation of symptoms, known abnormal results, pregnancy/postpartum concerns, active cancer workups, severe depression or suicidal thoughts, eating-disorder recovery, or complex medical decisions that need clinician context.

Measure before / after

Start with home blood pressure, medications/supplements, tobacco/nicotine and alcohol exposure, LDL-C/non-HDL-C and ApoB when useful, Lp(a) once, A1c or fasting glucose by age/risk, waist or body composition when actionable, kidney/liver markers when risk supports it, screening dates, vaccines, sleep apnea clues, activity, strength, balance, and family history. If considering MCED or whole-body MRI, measure the follow-up plan before the test: who interprets it, what counts as actionable, and what happens next.

What I’d do first

I would first close any abnormal-result or symptom loop, then confirm blood pressure, clarify ApoB/LDL/Lp(a) and metabolic risk, update standard screening, review tobacco/nicotine, alcohol, medications, vaccines, and safety risks, and build two reserve behaviors. Then I would discuss MCED or whole-body MRI only if the person understands the tradeoffs and the result would change care.

What would change my mind

A strong family history, premature ASCVD, very high LDL-C or Lp(a), pregnancy complications, PCOS, early menopause, diabetes, CKD, smoking history, abnormal screening result, falls, frailty, symptoms, medication risk, or a well-counseled decision to use MCED/whole-body MRI can change the order. An advanced test earns a place only if it changes the plan and has a follow-up path.

Frequently Asked Questions

What is a longevity audit?

A prioritized preventive health review. It ranks actions by absolute risk, preventability, actionability, evidence quality, and personalization instead of novelty.

Where do the hallmarks of aging fit?

They are the mechanism map, not the to-do list. Aging biology matters most when it translates into human, measurable, action-changing proxies.

What should I check first for longevity?

Red-flag symptoms and known abnormal results first. Then blood pressure, cardiovascular risk, tobacco, metabolic risk, age and risk appropriate cancer screening, alcohol, medications, vaccines, fitness, strength, sleep, nutrition, and family history.

Are biomarkers useful for longevity?

Yes, when they change decisions. Home blood pressure, ApoB or LDL-C/non-HDL-C, Lp(a) once, A1c or fasting glucose, eGFR/uACR in risk groups, and DXA when indicated can be high-yield. Broad panels can create noise.

Should I get a whole-body MRI?

Not as the first step for most people. It can find incidental findings and miss other risks. It should not outrank evidence-based screening, blood pressure, lipids, smoking, alcohol, metabolic risk, and cancer screening loops.

Should everyone get hormone testing?

No. Hormone evaluation is most useful when symptoms, transitions, fertility goals, bone risk, menstrual changes, menopause, PCOS, testosterone-deficiency symptoms, thyroid symptoms, or medication context make the result actionable.

Is a CGM worth it if I do not have diabetes?

Sometimes, but usually not first. CGM can help with diabetes, prediabetes, suspected hypoglycemia, or a focused short experiment. For metabolically healthy people, BP, lipids, activity, strength, sleep, nutrition, and alcohol often matter more first.

What is the best wearable for longevity?

For many adults, a validated home blood pressure cuff. Step count, sleep regularity, resting heart rate, estimated fitness, and HRV trends can help behavior, but wearables are not diagnostic tests.

How often should I do a longevity audit?

Yearly, or after major changes: new diagnosis, pregnancy/postpartum transition, menopause, new medication, major weight change, family-history discovery, surgery planning, serious illness, or a big training/lifestyle shift.

References & citations

Next step

Turn the guide into the right next decision.

If this page raised a real clinical question, start with the practice details. If you are still learning, get the weekly letter. If you are comparing tests, use the testing hub before buying another panel.

See clinical care Get the weekly letter Compare testing